
zzso is a weight control drug that zzso the zzso of both zzso and zzso In animals, it reduces food intake and increases zzso and preliminary data in human beings showed weight zzso This paper reports a zzso zzso study to determine the effect of zzso on body weight of patients with zzso 

Seven clinical centers screened zzso patients with obesity and zzso zzso to 24 weeks of treatment with 1 of 6 doses of zzso zzso 5, 10, 15, 20, or 30 zzso or zzso once zzso Six hundred zzso patients completed the zzso A two-week zzso zzso period was used to initiate a standardized program of diet, physical activity, and lifestyle zzso 

Weight loss was zzso and statistically significant zzso zzso zzso across all zzso for a 5 zzso to 30 zzso dosage of zzso At week 24, percent weight loss from baseline for zzso was: zzso zzso 1 zzso zzso 5 zzso zzso 10 zzso zzso 15 zzso zzso 20 zzso zzso and 30 zzso zzso Weight loss achieved at week 4 was zzso of weight loss achieved at week zzso Patients losing weight demonstrated an increase in serum high density zzso cholesterol and reductions in serum zzso total cholesterol, low density zzso cholesterol, and zzso zzso Small mean increases in blood pressure and pulse rate (with considerable individual zzso were observed in patients treated with zzso The most frequent adverse events were dry mouth, zzso and zzso 

zzso administered once daily for 24 weeks in the weight loss phase of treatment for uncomplicated obesity produced zzso weight loss and was well zzso zzso in serum lipids and zzso acid accompany zzso weight zzso Most of the adverse events observed on zzso are related to its zzso including small mean increases in blood pressure and heart zzso 

